Protalix BioTherapeutics, Inc. (AMEX: PLX) is a Healthcare company (Biotechnology) with a market capitalization of $243M. The Maz Rating grades it against the other companies in its sector.
Protalix BioTherapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $2.88, Protalix BioTherapeutics, Inc. trades at 11.0x trailing earnings, 2.9x sales and 2.9x book value, with an EV/EBITDA of 8.1. Over the last twelve months it generated about $85M of revenue and $22M of net income. It runs a gross margin of 71.2%, an operating margin of 29.8% and a net margin of 24.3%. It shows return on equity of 30.7%, return on invested capital of 22.3% and a free cash flow yield of 6.2%. On the balance sheet: a debt-to-equity ratio of 0.11 and a current ratio of 3.27. Over the past 52 weeks the share price ranged from $1.65 to $3.19, with a beta of 0.01.
Protalix BioTherapeutics, Inc. does not currently pay a dividend.
7 Wall Street analyst ratings cover the stock: 5 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.